Zhejiang Orient Gene Biotech Co Ltd (688298) - Total Liabilities

Latest as of September 2025: CN¥1.01 Billion CNY ≈ $148.51 Million USD

Based on the latest financial reports, Zhejiang Orient Gene Biotech Co Ltd (688298) has total liabilities worth CN¥1.01 Billion CNY (≈ $148.51 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 688298 cash generation efficiency to assess how effectively this company generates cash.

Zhejiang Orient Gene Biotech Co Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how Zhejiang Orient Gene Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Zhejiang Orient Gene Biotech Co Ltd's assets to evaluate the company's liquid asset resilience ratio.

Zhejiang Orient Gene Biotech Co Ltd Competitors by Total Liabilities

The table below lists competitors of Zhejiang Orient Gene Biotech Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Shenzhen Aoto Electronics Co Ltd
SHE:002587
China CN¥616.77 Million
Dook Media Group Limited
SHE:301025
China CN¥93.88 Million
MAS Financial Services Limited
NSE:MASFIN
India Rs102.87 Billion
Transcat Inc
NASDAQ:TRNS
USA $176.12 Million
Daily Journal Corp
NASDAQ:DJCO
USA $146.36 Million
Western Copper and Gold Corp
TO:WRN
Canada CA$5.48 Million
Sichuan Kexin Mechanic Electric
SHE:300092
China CN¥663.71 Million
Advanced Nano Products Co. Ltd
KQ:121600
Korea ₩203.23 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Zhejiang Orient Gene Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688298 market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.28 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.16 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.14 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Zhejiang Orient Gene Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Zhejiang Orient Gene Biotech Co Ltd (2016–2024)

The table below shows the annual total liabilities of Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥1.30 Billion
≈ $190.69 Million
-9.89%
2023-12-31 CN¥1.45 Billion
≈ $211.63 Million
-39.25%
2022-12-31 CN¥2.38 Billion
≈ $348.38 Million
+14.01%
2021-12-31 CN¥2.09 Billion
≈ $305.57 Million
+86.14%
2020-12-31 CN¥1.12 Billion
≈ $164.16 Million
+944.66%
2019-12-31 CN¥107.38 Million
≈ $15.71 Million
-17.15%
2018-12-31 CN¥129.62 Million
≈ $18.97 Million
+6.94%
2017-12-31 CN¥121.20 Million
≈ $17.74 Million
-14.82%
2016-12-31 CN¥142.28 Million
≈ $20.82 Million
--

About Zhejiang Orient Gene Biotech Co Ltd

SHG:688298 China Medical Devices
Market Cap
$672.61 Million
CN¥4.60 Billion CNY
Market Cap Rank
#11094 Global
#3299 in China
Share Price
CN¥22.80
Change (1 day)
+2.10%
52-Week Range
CN¥21.90 - CN¥29.94
All Time High
CN¥221.47
About

Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunologic… Read more